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A B S T R A C T
Introduction: Epileptic seizures in stroke patients are a common complication and adversely affect
neurological outcome. We tried to perform a trial aimed at preventing the development of late
poststroke seizures using levetiracetam. Levetiracetam is assumed to have anti-epileptogenic properties
and might be suitable to prevent late epileptic seizures in stroke patients.
Methods: Stroke patients with a cortical syndrome and a modiﬁed Rankin score  3 or NIHSS  6 were
treated with either levetiracetam 1500 mg daily divided in two doses or placebo during 12 weeks
following stroke. Treatment was started within 7 days following stroke onset.
Results: Only 16 patients were included in this trial. Problems during the execution of this prophylactic
trial concerned the assessment of the occurrence of epileptic seizures, a very slow inclusion rate, the use
of anticonvulsive co-medication, continuation of the trial medication after discharge, and the evaluation
of possible side effects of the trial medication.
Discussion: Due to too few participants, no conclusions could be drawn regarding the ability of
levetiracetam to prevent poststroke seizures. The problems encountered during execution of this trial
seem to be inherent to performing a trial aimed at preventing the development of epileptic seizures in
stroke patients.
Conclusions: A prophylactic trial in stroke patients aimed at preventing poststroke seizures and epilepsy
seems not feasible.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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In the Netherlands 41,000 patients suffer a stroke annually.1
Late epileptic seizures develop in 2.5–15% of stroke patients.2–12
Recurrent late symptomatic epileptic seizures develop in 48–89%
of stroke patients with a ﬁrst late seizure.2,5,12,13
The occurrence of a late epileptic seizure or epilepsy in stroke
patientsmay adversely affect their outcome. Bogousslavsky et al.14
described a persistent worsening of neurological outcome follow-
ing epileptic seizures in stroke patients. De Reuck et al.15 described
a lower Mini-Mental State Examination score and a higher
modiﬁed Rankin score (mRS), implying worsening of neurological
state in stroke patients with epilepsy compared to stroke patients
without epilepsy. In patients with intracerebral haemorrhage, the
occurrence of epileptic seizures is associated with an increase in* Corresponding author. Present address: P.O. Box 9015, 6500 GS, Nijmegen, The
Netherlands. Tel.: +31 24 8483148; fax: +31 84 8302894.
E-mail address: jordie.vantuijl@gmail.com (J.H. van Tuijl).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.12.012midline shift and a worsening of neurological outcome.16 In
contrast with these results, Paolucci et al.12 described no inﬂuence
of epileptic seizures on rehabilitation outcome. The inﬂuence of
epileptic seizures in stroke patients on mortality remains
unclear.17–20
The pathophysiology of the development of early and late
epileptic seizures is unclear. Several authors21,22 suggested a
different pathophysiological process underlying both conditions.
Late seizures are assumed to be the result of the complex process of
epileptogenesis during which the seizure threshold is lowered
through a complicated chain of neuronal changes, whereas early
seizuresmay rather be the result of acute excitatory activity due to
glutamate release. Therefore, in our trial we focused on the
prevention of late seizures only.
In the ideal situation patients with a high risk of developing late
epileptic seizures should be treated prophylactically with a drug
that prevents epileptogenesis and has few side effects. Several
antiepileptic drugs (AEDs) have been tested for their ability to
prevent seizures associated with fever, alcohol, malaria, perinatal
asphyxia, contrast media, tumors, craniotomy and traumatic brainvier Ltd. All rights reserved.
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at anti-epileptogenesis in stroke patients using an AED has been
published. The need for such a trial was suggested by several
authors.12,24 Recently, such a trial was also recommended in a
Cochrane review.25
In 2005 we started the ETLAS trial: ‘Early Treatment with
Levetiracetam After Stroke for the prevention of late seizures: a
randomised placebo-controlled double-blind trial’. The aim of our
trial was to investigate whether prophylactic treatment with an
AED following stroke reduced the risk of late epileptic seizures or
postponed the onset of late epileptic seizures or epilepsy.
For several reasonswewere unable to complete this trial. In this
paper we report the problems encountered by our group when
performing this prophylactic trial. We wanted to report this
negative result because in our opinion, the implementation
problems of this trial are inherent to this area and seem
unavoidable.
2. Methods
2.1. Design of the trial
The ETLAS trial was designed as a multicentre, randomised,
placebo-controlled, double-blind clinical trial. Primary endpoint of
the trial was a ﬁrst late epileptic seizure, deﬁned as an unprovoked
epileptic seizure more than 1 week after stroke.26 Secondary
endpoints were ‘time to event’ (period between stroke and the
occurrence of a late epileptic seizure), occurrence of early epileptic
seizures within 7 days after stroke, seizure severity, neurological
function, neurocognitive function, handicap score, quality of life,
and the occurrence of side effects of the trial medication. Fig. 1
illustrates the trial design.
The trial was approved by the local medical ethics committee
and board of directors of each participating centre. All patients or
their legal representatives gave their written informed consent.
Adult patients were recruited from the neurological ward at the
University Hospital Maastricht starting in August 2005. From
August 2006 the trial also started in the second centre, a large
peripheral hospital in the south of the Netherlands. Patients with
either lobar intracerebral haemorrhage or ischemic stroke with a
cortical syndrome and mRS  3 or National Institutes of Health
stroke severity (NIHSS) score  6 were asked to participate.
Exclusion-criteria were previous history of epilepsy or treatment
with an AED, life expectation less than 1 month due to stroke or[()TD$FIG]
Fig. 1. Trialother life-threatening comorbidity, and participation in another
intervention trial. Treatment with thrombolytic drugs was no
exclusion criterion. Trial medication was started between 48 h till
7 days after stroke. Patients were randomised to treatment with
levetiracetam (LEV) or placebo. Trial medication, provided by UCB
Pharma, consisted of either placebo tablets or 250 mg LEV tablets.
These tablets were used to make boxes which were ﬁlled at
random (according to a computerised randomisation list) by a
pharmacist, and given consecutive numbers from 1001, 1002, etc.
On each inclusion the trialmedicationwith the lowest numberwas
provided by the hospital pharmacist. The allocation of the trial
medication was therefore blind to the patient and the investiga-
tors. The trial medication was gradually increased. On the ﬁrst day
of inclusion the patient received twice daily 1 tablet, the second
day twice daily 2 tablets and the third day twice daily 3 tablets.
When tolerated, this dose was kept constant for 12 weeks, after
which the trial medication was tapered off by one tablet each 3
days and eventually discontinued. Total treatment time was
therefore 14 weeks and 3 days. The target dose of LEV was two
times daily 750 mg, but we allowed for lowering of the dose to
twice daily 500 mgor even twice daily 250 mgwhen side-effects or
medical problems, such as reduced renal clearance rate, occurred.
We informed the staff, nurses at the neurology wards and the
nursing home doctors at the referral nursing homes of ﬁrst choice
about our trial with an oral presentation and written information
on trial details. Also, in each patient chart a coloured leaf was
available with information on the trial and telephone numbers of
the trial investigators. On discharge from the hospital, a letter,
containing information about the trial, tapering schedule and
contact information was provided along with the trial medication.
2.2. Follow-up and outcome scores
Follow-up visits took place at week 1, 6, 16 and 52 after
inclusion, either at the outpatient clinic, in the nursing home,
rehabilitation centre or at the patients’ home. Atweek 26 andweek
39, the patients or their caregivers were contacted by telephone to
inquire about the occurrence of possible epileptic seizures. We
recorded the degree of handicap using the mRS, a six item scale
ranging from ‘0 = no symptoms at all’ to ‘6 = dead’, at inclusion,
week 6, 16, and 52. The NIHSS, a 15-item impairment scale which
total scores ranging from 0 to 42, with higher values reﬂecting a
higher stroke severity, was recorded at inclusion and at week 52.
The Barthel index (BI), which is a 10 item questionnaire aboutdesign.
J.H. van Tuijl et al. / Seizure 20 (2011) 285–291 287independence in activities of daily living (ADL), with scores ranging
from 0 to 20, in which ‘0’ signiﬁes total dependence and ‘20’ total
independence, was recorded at week 6, 16 and 52. The EuroQol, a
generic quality of lifemeasure, was recorded at the same follow-up
moments as the BI. The side-effect in AED treatment questionnaire
(SIDAED) was recorded at week 1 and week 6. This is a 46-item
scale, which includes items in several categories such as general
CNS, behaviour, depressive symptoms, and cognitive function (in
Fig. 2 all categories are listed). Of each item the severity of the
problem (mild, moderate, or severe) and the duration of the
problem (several weeks, several months, longer than 6 months)
was recorded.27
Neurocognitive function was tested using the Computerised
Visual Searching Task (CVST), an adaptation of Goldstein’s Visual
Searching Task, which is part of the FePsy computerised
neuropsychological test method.28 The CVST assessed mental
speed. Patients had to compare a centred grid pattern with 10
surrounding patterns, one of which was identical to the target
pattern. The test consisted of 20 trials and gave an indication of the
speed of information processing and perceptual mental strategies.
2.3. Sample size estimation
Sample size calculation was based on the following assump-
tions: (1) patients with a cortical syndrome and mRS  3 have a
risk of 13% of late seizures,29 (2) treatment reduces this risk (13%)
to 5% (RRR = 62%). The primary factor type-1 (a) was chosen at the
5% level. Statistical powerwas chosen to be 1  b = 80%. The power
calculation based on percentage difference (change from 13% to 5%
epilepsy) then yielded 200 patients per arm.
2.4. Discussion of the design
2.4.1. Trial population
The advantages of prophylactic medication in terms of
prevention of epileptic seizures must be balanced against the
disadvantages of treating all patients, which means taking
medication daily and being exposed to the risk of side effects,
especially for patients who would never had developed epileptic
seizures. To improve the balance between efﬁcacy of the drug and
[()TD$FIG]Fig. 2. Results of side-effect of antiepilethe occurrence of side effects, an effective drug with few side-
effects should be selected and only patients with a high risk of
developing poststroke epilepsy should be treated.
Several factors have been associated with the occurrence of late
epileptic seizures in stroke patients: age, stroke severity, stroke
localisation or cortical syndrome, stroke type, and the occurrence
of early seizures.6,11–13,30–37 Nonetheless, there is still debate
about which factors have a signiﬁcant contribution to the risk of
developing poststroke epileptic seizures. In our centre Heuts-van
Raak29 performed a prospective study in poststroke patients. They
reported a percentage of 13% late onset seizures in patients with an
ischemic stroke, clinically a cortical syndrome and a mRS  3. The
mRS is an outcome scale. It is more rational to use a stroke severity
scale when selecting patients eligible for a trial. Therefore, we
decided to use both the mRS and the NIHSS, a frequently used
stroke severity scale, as inclusion criterion. A NIHSS  6 was
chosen because, in our opinion this represented a stroke severity
with mRS  3 best.38
2.4.2. Trial medication
LEV is assumed to have anti-epileptogenic properties. Whenwe
started this study, this effect had been tested in several animal
models, e.g. amygdala kindled rats,39 corneally kindledmice,40 and
spontaneous epileptic rats.41,42 After initiation of our trial in 2005,
more reports have been published about the antiepileptogenic
effects of LEV in animal models.43–46 Sugaya et al.44 suggested that
prophylactic use of LEV for several weeks after a cerebral insult,
like cerebral infarction, could provide long-lasting protection in
the prevention of the late onset of spontaneous epilepsy.
Early treatment with LEV in stroke patients does not seem
harmful with regard to the effect on ischemic brain tissue.47
Tolerability of LEV in clinical practice is good.48–51 We choose a
target LEV dose of two times daily 750 mg, which is a clinically
accepted dose with acceptable tolerability and high enough to be
effective.
2.4.3. Start of treatment
An early start of treatment seemed necessary to allow for the
best possible anti-epileptogenic effects, when one considers
epileptogenesis as a continuous process which starts immediatelyptic drug (SIDAED) questionnaire.
Table 1
Reasons for not including stroke patients in the trial.
Reasons Percentage (%)
Non-cortical stroke (brainstem, cerebellar, lacunar) 25
Former history of stroke 13
Deep intracerebral haematoma, cerebellar hematoma, (suspicion of) bleeding in a braintumor, or subdural haematoma 13
Minor neurological deﬁcit (isolated symptoms like hemianopia, central facial palsy) 13
Somnolence (e.g. due to severe stroke or pneumonia) with inability to swallow, or pending death 11
A history of epileptic seizure(s) and/or AED use or acute symptomatic seizures requiring treatment 8
Uncertainty about etiology of neurological deﬁcit (e.g. confusion as presenting symptom, hypodensity on CT scan suspect for lowgrade
malignancy, or suspicion of a seizure causing neurological deﬁcit)
6
Admission for minor stroke and progression of neurological deﬁcit several days after admission, or occurrence of symptoms several days before
presentation in our hospital preventing inclusion within 7 days following stroke
5
Decreased renal function 3
Severe co-morbidity with a short life-expectancy 2
No informed consent possible (due to, e.g. aphasia or mental retardation, and no family members available to give consent) <1
Missed due to admission to other ward <1
History of other brain disease (e.g. pituitary tumor) <1
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provide extensive patient information to guarantee compliance for
the duration of 12 months, and to give patients and their relatives
time to consider inclusion in the trial, initiation of treatment was
not started within 48 h. To allow participation of patients who
could not give informed consent, e.g. due to somnolence in severe
stroke, we extended the inclusion period to 7 days after stroke.
2.4.4. Treatment duration and follow-up
The length of the intervention period (12 weeks) was based on
calculations from the study by Heuts-van Raak.29 Within the ﬁrst
year after stroke, the occurrence of late epileptic seizureswas evenly
distributed without peak periods. The treatment period should be
long enough to prevent epileptogenesis. However, longer treatment
periods increase the risk that treatment is anti-convulsive instead of
anti-epileptogenic, as some patients would have had epileptic
seizures if the AED would not have been given. The purpose of this
trialwas not to study the anti-convulsive effect of LEV, but to test the
hypothesis of an anti-epileptogenic or prophylactic effect.
The length of our follow-up periodwas based on data indicating
that approximately two third of the late epileptic seizures occur
within 1 year after stroke.11,13
2.4.5. Estimated inclusion rate
Before starting this trial we tried to estimate the number of
patients eligible for inclusion in this trial. In this period yearly
about 340 patients were admitted to our hospital with a stroke, of
which 62% had an ischemic strokewith a cortical syndrome, and 7%
had a lobar intracerebral haemorrhage (resulting in 235 available
patients per year). Because in this prophylactic trial only ﬁrst-ever
ischemic stroke patients with a predeﬁned severity were suitable
for inclusion, we estimated another 80 patients would not have the
required severity of neurological deﬁcit for inclusion or other
medical problems preventing inclusion (resulting in 155 available
patients per year). Furthermore, we estimated that two third
would give informed consent. Hence, we would be able to include
100 patients a year. So, in our centre 2 years would be sufﬁcient to
include 200 patients. By inviting a second hospital to include
similar numbers of patients, we supposed the necessary 400
patients could be included in 2 years, leading to a trial duration of 3
years, which seemed feasible.
3. Results
In the period from August 2005 until December 2006 we
included 16 patients from the department of Neurology at theUniversity Hospital Maastricht. No patients were included in the
second centre. Therefore, we decided to end the trial prematurely.
In this period about 500 patients were admitted to our hospital
with a stroke. Most patients, however, were not eligible for
inclusion. Table 1 gives an overview of the reasons to exclude
patients. It illustrates the most crucial problem that we encoun-
tered in our trial. The ‘label’ of stroke combines a heterogeneous
group of patients with a stroke andmany complicating factors. Due
to these factors, in addition to exclusion based on stroke type and
stroke severity, many patients were ineligible for this prophylactic
trial.
Only 31 of the 500 patients were eligible for our trial. Of these,
15 refused, and 16 gave informed consent. Of the 16 included
patients, nine patients were randomised to LEV, seven to placebo.
Reasons for the high refusal rate were fear of side-effects,
disapproval of the experimental character of the trial, whichmeant
a 50% chance of treatment with placebo (‘taking pills for nothing’)
or relatives thinking that the trial would give too large a burden to
the already ill patient. Patients were at a vulnerable phase in their
lives, they just suffered a major life event. They did not want to be
bothered with scientiﬁc investigations.
Table 2 shows results of themRS, NIHSS, BI, and VAS score of the
EuroQol per group and overall.
3.1. Primary endpoint
In four patients (4, 9, 12, 16) possible epileptic seizures were
reported. One episode was reported the day after the event; the
other episodes were only reported at the next follow-up visit.
In two patients a diagnosis of late epileptic seizures was
considered by the treating physician: in patient 9, who was
randomised to placebo and in patient 16, who was randomised to
LEV. After revision of the chart of patient 9 by one of our
experienced neurologists (MdK), the diagnosis poststroke epilepsy
was conﬁrmed. This patient received carbamazepine (CBZ) to treat
his poststroke seizures and because seizures recurred, LEV was
added.
Patient 16 had absence-like episodes and collapses. She was
treated with CBZ because her treating physician considered these
episodes to be poststroke epilepsy. After several weeks of CBZ
treatment, she had a pacemaker implanted because of a sick sinus
syndrome. The collapses then disappeared. After revision of her
medical chart the diagnosis of poststroke epilepsy was considered
very unlikely by our experienced neurologist (MdK).
In patients 4 and 12, both randomised to LEV, the episodes were
diagnosed as vasovagal collapse and both a vasovagal collapse and
a recurrent stroke, respectively.
Table 2
Patient characteristics by group (LEV vs. placebo) and overall: number of patients;
mean values and standard deviation between brackets of age, gender, stroke type,
modiﬁed Rankin score, NIH stroke scale, Barthel index and quality of life
questionnaire VAS score.
Levetiracetam Placebo Total
Number of patients 9 7 16
Age in years (SD) 66.0 (14.1) 69.6 (9.9) 67.6 (12.2)
Gender (male/female) 3 M/6 F 5 M/2 F 8 M/8 F
Ischemic/hemorrhagic stroke 7 I/2 H 7 I/0 H 14 I/2 H
mRS on inclusion (SD) 3.8 (0.4) 4.3 (0.5) 4.0 (0.5)
mRS at 1 year (SD) 2.9 (1.5) 3.6 (0.5) 3.2 (1.2)
NIHSS on inclusion (SD) 10.0 (3.6) 14.6 (3.7) 12.0 (4.2)
NIHSS at 1 year (SD) 5.3 (4.1) 10.8 (4.7) 7.6 (5.1)
BI at week 6 (SD) 13.9 (5.9) 6.8 (8.0) 11.2 (7.4)
BI at week 16 (SD) 14.6 (6.4) 9.5 (8.1) 12.9 (7.1)
BI at 1 year (SD) 13.1 (7.2) 7.0 (7.8) 10.8 (7.7)
EuroQol-VAS at week 6 (SD) 6.8 (1.5) 4.8 (2.4) 6.0 (2.0)
EuroQol-VAS at week 16 (SD) 6.5 (1.3) 5.5 (3.1) 6.1 (2.1)
EuroQol-VAS at 1 year (SD) 7.0 (1.8) 4.8 (2.8) 6.1 (2.5)
M=male, F = female, I = ischemic stroke, H= intracranial haemorrhage, mRS=mo-
diﬁed Rankin score, NIHSS=NIH stroke severity score, BI =Barthel index, EuroQol-
VAS=VAS score on the Euro-QOL.
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Five patients were treated with co-medication which may have
inﬂuenced the occurrence of epileptic seizures. During follow-up,
two patients (9, 16) received AEDs because they were diagnosed as
having poststroke seizures (correctly in patient 9, undeserved in
patient 16). Two patients (3, 11) received AEDs to treat neuropathic
pain due to a thalamic syndrome. Patient 3 was treated with
carbamazepine and patient 11 with pregabalin. Two patients (5, 9)
used benzodiazepines as sleep medication. Without this co-
medication, we would possibly have recorded more epileptic
seizures during follow-up.
3.3. Side effects
To evaluate the impact of side-effects during the treatment
with LEV, the SIDAED questionnaire was recorded. At the ﬁrst
follow-up after inclusion, which is one week after start of the
trial medication, 12 patients completed the SIDAED list. Data
from four patients are missing: patient 13 died 6 days after
inclusion, patient 12 had severe aphasia preventing adequate
answers to the questions, patient 7 had behavioural problems
(agitation and anxiety) and could not cooperate, and in patient
16 the list was forgotten at this follow-up point. At 6 weeks
follow-up 4 patients did not ﬁll out the questionnaire: three
died (4, 13, 14), and patient 12 still had severe aphasia.
Therefore, the questionnaire was not recorded in 30% of the
patients at both weeks 1 and 6. Patient 11 stopped taking the
trial medication one week after initiation of the trial and
therefore her side-effect list at week 6 can neither be used as a
follow-up parameter in the LEV group, nor in the placebo group
because she stopped taking her trial medication.
Fig. 2 shows the percentage of problems per category, which
were reported at week 1 and week 6. The number of problems at
week 1 is higher in the LEV group than in the placebo group.
However, some of these problems were reported to exist several
months or longer than 6months. Therefore, these problems cannot
be caused by either stroke or side-effects of the trialmedication but
must reﬂect longer existing premorbid problems.
At week 6 no clear differences in complaints existed between
the LEV and placebo group. Because data were not available for all
patients at both follow-up points, comparison of the overall results
at week 1 and 6 is not possible.3.4. Adjustment of trial medication dose or discontinuation of trial
medication
Patients 3, 15 and 16 received a lower dose of the trial
medication due to renal dysfunction.
In patient 3 the trial medication was discontinued by his
treating nursing home doctor without further consultation with
the trial team and without tapering off the trial medication when
the patient was transferred to a nursing home 48 days after
inclusion in our trial. After unblinding the trial medication proved
to be placebo.
In patient 9 the family requested lowering of the dose because
of fear of side-effects (dizziness, cognitive complaints). He
appeared to be treated with placebo.
The family of patient number 11 demanded discontinuation of
the trial medication one week after start of the trial medication,
because of the occurrence of visual hallucinations. As hallucina-
tions have been reported as a side effect of LEV we tapered off the
trial medication and discontinued it 20 days after start of the trial.
She had been treated with LEV.
3.5. Lost to follow-up or died during follow-up
Three patients died during follow-up (4, 13, 14), two of them
received placebo, one received LEV. Patient 4 died in a nursing
home. The coroner concluded this was caused by a second
intracranial haemorrhage (autopsy was not performed). Patient 13
died 5 days after start of trial medication due to massive lung
embolism (conﬁrmed on autopsy). Patient 14 died at home.
Paramedics concluded that a cardiac arrest was the cause of death
(no autopsy).
In patient 16 follow-up at 1 year after inclusion was by
telephone with a nurse. No visit was allowed due to a bad
neurological state.
4. Discussion
The need for clinical studies to investigate the beneﬁts of
prophylactic treatment to prevent poststroke epilepsy is clear.25
However, inherent to such a trial is a plethora of difﬁculties that
has also been discussed by Herman.52 In this paper we discuss the
problems we met and which resulted in a premature ending of our
trial.
Only 16 patients (nine treated with LEV, seven with placebo)
were included in the trial. One patient in the placebo group
developed poststroke epilepsy. The number of included patients is
far too low to determine the possible anti-epileptogenic effect of
LEV in stroke patients. This paper intends to disclose the problems
encountered in order to prevent future prophylactic trial failures.
The problems and complicating factors can be summarised as
follows:1. As shown in the results section selecting sufﬁcient patients
eligible for inclusion was difﬁcult. Calculations based on our
stroke registry did not give an adequate estimate of the number
of patients suitable for inclusion. The majority of the patients
either met exclusion criteria or had such co-morbidity that
inclusion is impossible for practical reasons. With the present
in- and exclusion criteria, each centre will only have a limited
number of eligible patients. This means that a large multicentre
and probably multinational trial is required to include sufﬁcient
patients in an anti-epileptogenesis trial.2. The assessment of seizure like episodes in stroke patients was
difﬁcult. The occurrence of epileptic seizures may be missed by
the patient itself, health personnel and family members.53 In
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were not mentioned to the examiner immediately. Generally,
they were mentioned at the next follow-up visit, either
spontaneously or on request, which caused a recall-bias. Some
episodes may never have been mentioned. Seizures in stoke
patients, in particular complex partial seizures may be difﬁcult
to recognize.54 The differential diagnostic considerations
included stroke recurrence, vasovagal collapse, limb shaking
TIA, hypoglycaemia or other metabolic disturbances, cardiac
arrhythmias with syncope, and hyperventilation.55,56 Therefore,
measurement of the primary endpoint, the occurrence of late
epileptic seizures, was difﬁcult.3. Furthermore, the use of benzodiazepines and AEDs as co-
medication caused a problem in this trial because these drugs
have potential anticonvulsive effects. Without this co-medica-
tion, we would possibly have recorded more epileptic seizures
during follow-up. These drugs were mostly prescribed by other
treating physicians (general physician, rehabilitation doctor,
nursing home doctor). This is part of good clinical practice, and
could not be avoided.4. A further difﬁculty in our trial was the evaluation of side-effects
occurring during the administration of the trial medication. A
reliable assessment of side-effects was considered important in
order to balance the beneﬁcial effects of preventing poststroke
seizures, on the one hand, and the risk and severity of side-
effects when using prophylactic medication, on the other hand.
In this trial, symptoms which occurred during treatment
with the trial medication may be related to the stroke, to co-
medication which is started at the onset of stroke, to co-
medication used prior to the stroke or to the trial medication.
Furthermore, aphasia or inability to cooperate otherwise may
limit the report of side effects of the trial medication.
At the ﬁrst evaluation point at week 1, patients in the LEV
group reported more possible side-effects than patients in the
placebo group. However, part of these complaints were found to
exist already before the trial medication was started and even
before the stroke, and therefore could not be ascribed to
treatment with the trial medication. At week 6 there were no
differences in number of possible side effects. This could point to
a disappearance of side-effects of the trial medication or co-
medication due to habituation, but also to a neurological
recovery from stroke. A third explanation is that complaints
which existed before the stroke may disappear to the
background due to new complaints as a consequence of stroke
and newmedication. Evaluation of side-effects in patientswith a
recent stroke is also difﬁcult because many complaints caused
by a stroke are the same as complaints caused by side-effects of
AEDs.5. Continuation of trial medication after discharge from the
neurological ward is an additional problem. Most stroke
patients were admitted to the neurological ward for a limited
period of time. After several days or, in some patients, weeks,
patients were transferred to a nursing home or rehabilitation
centre. Informing other health care workers (nurses, doctors) is
crucial but also very difﬁcult. Despite our measures to inform
other health care personnel, as described in themethods section,
continuation of trial medication after discharge appeared to be
difﬁcult. Also continuation of the trial medication when a
patient was readmitted to our hospital for a non-neurological
reason on another ward was difﬁcult.6. The inﬂuence of thrombolytic drugs has to be considered. Hafeez
et al.57 reported on a partial status epilepticus following
administration of a thrombolytic drug. Rodan et al.58 reported
three patients with epileptic seizures following thrombolysis
each with very good neurological recovery. A recent reportsuggests that thrombolysismay partly prevent the occurrence of
late-onset seizures, probably by a better reperfusion of the
ischemic brain regions.59We believe that stroke patients treated
with a thrombolytic drug should not be excluded in a trial aimed
at preventing poststroke seizures.
5. Conclusions
The problems arising in a prophylactic trial aimed at preventing
poststroke seizures concern difﬁculties in assessing the primary
endpoint, which is the occurrence of a ﬁrst late epileptic seizure, a
very slow inclusion rate due to few eligible patients, the use of co-
medication with anticonvulsive properties, difﬁculties to maintain
patients on their treatment regimen during the trial, and
difﬁculties in evaluating possible side effects of the trial medica-
tion.
In our opinion a prophylactic trial assessing the anti-epilepto-
genic efﬁcacy of a short AED treatment period to prevent
poststroke epilepsy is not feasible.References
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